IRWD Stock Analysis: Buy, Sell, or Hold?
IRWD - Ironwood Pharmaceuticals, Inc. - Class A
$3.90
0.39 (11.11%)
▲
5d:
+22.26%
30d:
+7.14%
90d:
+17.12%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
IRWD is down 7.6% this week, but smart money is accumulating calls. Top strike: $4 2026-05-15 with 419 OI. Call ratio: 100% View Scanner →
Strength: 8.8/10
Get Alerted When IRWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IRWD shows positive signals but monitor for confirmation. Market pricing in 18.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: IRWD shows positive signals but monitor for confirmation. Market pricing in 18.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.72
Based on 5.9% avg growth
INTRINSIC VALUE TODAY
$6.04
35.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRWD is currently trading at $3.90, which is considered extended relative to its 30-day fair value range of $3.19 to $3.68. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.7) compared to its historical average (5.0). Remarkably, the market is currently pricing in an annual earnings decline of 18.7% over the next few years. This pessimistic expectation contrasts with the company's recent 1046.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRWD is in a strong uptrend. The price is approaching resistance at $3.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.1% recently.
Market Sentiment: IRWD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.10 (+56.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IRWD is in a strong uptrend. The price is approaching resistance at $3.77. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 11.1% recently.
Market Sentiment: IRWD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.10 (+56.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$3.19 -
$3.68
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range (+6.0% above fair value)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+11.1%)
- BULLISH: Trading 56.4% below Wall St target ($6.10)
Fair Price Analysis
30-Day Fair Range
$3.19 -
$3.68
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$3.02
Resistance Level
$3.77
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.68
Wall Street Target
$6.10
(+56.4%)
Revenue Growth (YoY)
-47.3%
Earnings Growth (YoY)
1046.8%
Profit Margin
8.1%
Valuation Discount vs History
-18.7% cheaper
PE vs Historical
2.7 vs 5.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-18.7%
(market-implied from PE analysis)
1-Year Target
$3.51
(-10%)
2-Year Target
$3.16
(-19%)
3-Year Target
$2.84
(-27%)
3-Yr Target (if PE normalizes)
(PE: 3→5)
$5.31
(+36%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 7.9%)
$40.90
(+949%)
Base:
(SPY PE: 2.7, Growth: 7.9%)
$4.90
(+26%)
Bear:
(PE: 2.3, Growth: 7.9%)
$4.16
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 20.27 | Current EPS (TTM): $0.15
Bull Case
$6.69
(+103%)
Analyst growth 100.0%, PE expands to 22.3
Base Case
$6.08
(+85%)
Market implied 100.0%, PE stable at 20.3
Bear Case
$2.07
(-37%)
Severe decline -20.0%, PE contracts to 17.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.7 to 5.0
Stabilization Target:
$7.28
(+86.8%)
PE Expansion Potential:
+86.8%
Share & Embed Analysis
Last updated: April 02, 2026 4:15 AM ET
Data refreshes hourly during market hours. Next update: 5:15 AM
Data refreshes hourly during market hours. Next update: 5:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alexander J Denner
SELL
6730800 shares
2026-03-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$178 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$151 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$91 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 65 BUY |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$38 | 64 BUY |
